Equity Analysis /
United States of America

US : Immunovant, Inc. - IMVT | R&D Day Takeaways: Ph 3 MG Trial On-Track for 1H Launch; Color on Next Indications by August

    Danielle Brill
    CGS-CIMB
    30 March 2022
    Published by